Literature DB >> 12421926

TRAIL/Apo-2 ligand induces primary plasma cell apoptosis.

Josie Ursini-Siegel1, Wenli Zhang, Anne Altmeyer, Eunice N Hatada, Richard K G Do, Hideo Yagita, Selina Chen-Kiang.   

Abstract

Apoptosis constitutes the primary mechanism by which noncycling plasma cells are eliminated after the secretion of Ag-specific Abs in a humoral immune response. The underlying mechanism is not known. Here, we demonstrate that the expression of both TRAIL/Apo-2 ligand and the death receptors (DR) DR5 and DR4, but not Fas, are sustained in IL-6-differentiated Ig-secreting human plasma cells as well as primary mouse plasma cells generated in a T-dependent immune response. Plasma cell apoptosis is induced by both endogenous and exogenous TRAIL ex vivo, suggesting that TRAIL-mediated killing may, in part, be plasma cell autonomous. By contrast, resting and activated B cells are resistant to TRAIL killing despite comparable expression of TRAIL and DRs. The preferential killing of plasma cells by TRAIL correlates with decreased expression of CD40 and inactivation of NF-kappaB. These results provide the first evidence that primary plasma cells synthesize TRAIL and are direct targets of TRAIL-mediated apoptosis, which may relate to the inactivation of the NF-kappaB survival pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421926     DOI: 10.4049/jimmunol.169.10.5505

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  B lymphocytes are resistant to death receptor 5-induced apoptosis.

Authors:  Roslyn N Crowder; Hong Zhao; W Winn Chatham; Tong Zhou; Robert H Carter
Journal:  Clin Immunol       Date:  2011-01-28       Impact factor: 3.969

Review 2.  TRAIL, Bim, and thymic-negative selection.

Authors:  Shi-Jun Zheng; Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Dendritic Cells Regulate Extrafollicular Autoreactive B Cells via T Cells Expressing Fas and Fas Ligand.

Authors:  Michelle L Ols; Jaime L Cullen; Adriana Turqueti-Neves; Josephine Giles; Mark J Shlomchik
Journal:  Immunity       Date:  2016-10-25       Impact factor: 31.745

4.  A critical role of TRAIL expressed on cotransplanted hepatic stellate cells in prevention of islet allograft rejection.

Authors:  Horng-Ren Yang; Ching-Chuan Hsieh; Lianfu Wang; John J Fung; Lina Lu; Shiguang Qian
Journal:  Microsurgery       Date:  2010-05       Impact factor: 2.425

5.  Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Authors:  Wan Cheung Cheung; Joong Su Kim; Michael Linden; Liangping Peng; Brian Van Ness; Roberto D Polakiewicz; Siegfried Janz
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

6.  Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.

Authors:  Claire L Dobson; Sarah Main; Philip Newton; Matthieu Chodorge; Karen Cadwallader; Robin Humphreys; Vivian Albert; Tristan J Vaughan; Ralph R Minter; Bryan M Edwards
Journal:  MAbs       Date:  2009-11-11       Impact factor: 5.857

7.  TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects.

Authors:  Vinh Nguyen; Cornelia Cudrici; Valentina Zernetkina; Florin Niculescu; Horea Rus; Cynthia Drachenberg; Violeta Rus
Journal:  Clin Immunol       Date:  2009-04-05       Impact factor: 3.969

8.  CD27+ B cells from a subgroup of common variable immunodeficiency patients are less sensitive to apoptosis rescue regardless of interleukin-21 signalling.

Authors:  A Clemente; J Pons; N Lanio; N Matamoros; J M Ferrer
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

9.  Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors.

Authors:  Sefat E Khuda; William M Loo; Siegfried Janz; Brian Van Ness; Loren D Erickson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

Review 10.  Systemic lupus erythematosus and apoptosis: a question of balance.

Authors:  Dror Mevorach
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.